CY1106187T1 - REPRESSION GENE - Google Patents

REPRESSION GENE

Info

Publication number
CY1106187T1
CY1106187T1 CY20061101430T CY061101430T CY1106187T1 CY 1106187 T1 CY1106187 T1 CY 1106187T1 CY 20061101430 T CY20061101430 T CY 20061101430T CY 061101430 T CY061101430 T CY 061101430T CY 1106187 T1 CY1106187 T1 CY 1106187T1
Authority
CY
Cyprus
Prior art keywords
gene
modulating
tumor suppressor
encode polypeptides
polypeptides capable
Prior art date
Application number
CY20061101430T
Other languages
Greek (el)
Inventor
Xin Lu
Original Assignee
Ludwig Institute For Cancer Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0019018A external-priority patent/GB0019018D0/en
Priority claimed from GB0029996A external-priority patent/GB0029996D0/en
Priority claimed from GB0112890A external-priority patent/GB0112890D0/en
Application filed by Ludwig Institute For Cancer Research filed Critical Ludwig Institute For Cancer Research
Publication of CY1106187T1 publication Critical patent/CY1106187T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Audible-Bandwidth Dynamoelectric Transducers Other Than Pickups (AREA)
  • Bipolar Transistors (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Η εφεύρεση σχετίζεται με την ταυτοποίηση ενός νέου μέλους της οικογένειας των γονιδίων καταστολής νεοπλασίας (πρωτεϊνών διέγερσης της απόπτωσης ASP's) που κωδικοποιούν πολυπεπτίδια ικανά να διαμορφώνουν τη δράση του γονιδίου p53 και κωδικοποιούν επίσης και πολυπεπτίδια ικανά να διαμορφώνουν τη δράση του εν λόγω πολυπεπτιδίου καταστολής νεοπλασίας.The invention relates to the identification of a new member of the family of tumor suppressor genes (apoptosis stimulating proteins ASP's) that encode polypeptides capable of modulating the activity of the p53 gene and also encode polypeptides capable of modulating the action of said tumor suppressor polypeptide.

CY20061101430T 2000-08-04 2006-10-04 REPRESSION GENE CY1106187T1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB0019018A GB0019018D0 (en) 2000-08-04 2000-08-04 Suppressor gene
GB0029996A GB0029996D0 (en) 2000-12-08 2000-12-08 Suppressor gene
GB0112890A GB0112890D0 (en) 2001-05-26 2001-05-26 Suppressor Gene
PCT/GB2001/003524 WO2002012325A2 (en) 2000-08-04 2001-08-06 Suppressor gene

Publications (1)

Publication Number Publication Date
CY1106187T1 true CY1106187T1 (en) 2011-06-08

Family

ID=27255828

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20061101430T CY1106187T1 (en) 2000-08-04 2006-10-04 REPRESSION GENE

Country Status (14)

Country Link
US (1) US20040053262A1 (en)
EP (2) EP1313762B1 (en)
JP (1) JP2004525605A (en)
CN (1) CN1310942C (en)
AT (1) ATE332309T1 (en)
AU (2) AU7651501A (en)
CA (1) CA2417368A1 (en)
CY (1) CY1106187T1 (en)
DE (1) DE60121346T8 (en)
DK (1) DK1313762T3 (en)
ES (1) ES2269430T3 (en)
HK (1) HK1057377A1 (en)
PT (1) PT1313762E (en)
WO (1) WO2002012325A2 (en)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6852108B2 (en) 2002-05-14 2005-02-08 Spiration, Inc. Apparatus and method for resecting and removing selected body tissue from a site inside a patient
ATE425183T1 (en) 2002-10-07 2009-03-15 Ludwig Inst For Cancer Res Ltd P53 BINDING POLYPEPTIDE
GB0223187D0 (en) * 2002-10-07 2002-11-13 Ludwig Inst Cancer Res Screen
EP1690094A1 (en) * 2003-12-04 2006-08-16 Ludwig Institute For Cancer Research Screening assay and treatment
WO2005054509A2 (en) * 2003-12-04 2005-06-16 Ludwig Institute For Cancer Research Assay and treatment
GB0328690D0 (en) 2003-12-10 2004-01-14 Ludwig Inst Cancer Res Tumour suppressor protein
WO2005093098A1 (en) * 2004-03-12 2005-10-06 Ludwig Institute For Cancer Research Differential drug sensitivity
EP1819827B1 (en) * 2004-12-08 2010-08-11 Cedars-Sinai Medical Center Methods for diagnosis of crohn's disease
US9051572B2 (en) 2005-01-20 2015-06-09 Ryboquin Company Limited Modulators of Itch ubiquitinase activity
US20100035257A1 (en) * 2006-10-06 2010-02-11 The General Hospital Corporation Methods to determine the responsiveness to cisplatin treatment
US20100021917A1 (en) * 2007-02-14 2010-01-28 Cedars-Sinai Medical Center Methods of using genes and genetic variants to predict or diagnose inflammatory bowel disease
US20100190162A1 (en) * 2007-02-26 2010-07-29 Cedars-Sinai Medical Center Methods of using single nucleotide polymorphisms in the tl1a gene to predict or diagnose inflammatory bowel disease
US20100015156A1 (en) * 2007-03-06 2010-01-21 Cedars-Sinai Medical Center Diagnosis of inflammatory bowel disease in children
WO2008116150A2 (en) 2007-03-21 2008-09-25 Cedars-Sinai Medical Center Ileal pouch-anal anastomosis (ipaa) factors in the treatment of inflammatory bowel disease
WO2008134569A2 (en) * 2007-04-26 2008-11-06 Cedars-Sinai Medical Center Diagnosis and treatment of inflammatory bowel disease in the puerto rican population
US20100144903A1 (en) * 2007-05-04 2010-06-10 Cedars-Sinai Medical Center Methods of diagnosis and treatment of crohn's disease
US20110177969A1 (en) * 2008-10-01 2011-07-21 Cedars-Sinai Medical Center The role of il17rd and the il23-1l17 pathway in crohn's disease
WO2010062960A2 (en) 2008-11-26 2010-06-03 Cedars-Sinai Medical Center METHODS OF DETERMINING RESPONSIVENESS TO ANTI-TNFα THERAPY IN INFLAMMATORY BOWEL DISEASE
US9580752B2 (en) 2008-12-24 2017-02-28 Cedars-Sinai Medical Center Methods of predicting medically refractive ulcerative colitis (MR-UC) requiring colectomy
JP2013504586A (en) * 2009-09-10 2013-02-07 メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ Methods and materials for modulating deubiquitinating enzymes and ubiquitinated polypeptides
EP2820041B1 (en) 2012-03-02 2017-06-14 Ludwig Institute For Cancer Research Ltd. Iaspp phosphorylation and metastatic potential
BR112015024752A2 (en) 2013-03-27 2017-07-18 Cedars Sinai Medical Center mitigation and reversal of fibrosis and inflammation through inhibition of tl1a function and related signaling pathways
WO2015010108A1 (en) 2013-07-19 2015-01-22 Cedars-Sinai Medical Center Signature of tl1a (tnfsf15) signaling pathway
CN106874709B (en) * 2015-12-12 2019-03-01 北京大学 The detection and bearing calibration of sequence data mistake in sequencing result
CA3005671A1 (en) 2015-11-19 2017-05-26 Peking University Methods for obtaining and correcting biological sequence information
US11186872B2 (en) 2016-03-17 2021-11-30 Cedars-Sinai Medical Center Methods of diagnosing inflammatory bowel disease through RNASET2

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5876950A (en) * 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
US5977311A (en) * 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
EP1117791A2 (en) * 1998-10-05 2001-07-25 Ludwig Institute For Cancer Research Cancer associated antigens and uses therefor
US7141384B1 (en) * 1998-10-06 2006-11-28 Georgetown University Detection of pleiotrophin
EP1146054A4 (en) * 1998-12-03 2003-08-06 Ono Pharmaceutical Co ReL1A BINDING INHIBITOR, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF
CA2402563A1 (en) * 1999-12-23 2001-07-26 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001057190A2 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides

Also Published As

Publication number Publication date
AU2001276515B2 (en) 2006-10-12
DE60121346T8 (en) 2007-12-13
DE60121346D1 (en) 2006-08-17
ES2269430T3 (en) 2007-04-01
WO2002012325A2 (en) 2002-02-14
EP1313762A2 (en) 2003-05-28
EP1710582A2 (en) 2006-10-11
AU7651501A (en) 2002-02-18
ATE332309T1 (en) 2006-07-15
WO2002012325A3 (en) 2003-03-06
HK1057377A1 (en) 2004-04-02
EP1313762B1 (en) 2006-07-05
EP1710582A3 (en) 2006-11-02
CA2417368A1 (en) 2002-02-14
PT1313762E (en) 2006-11-30
CN1310942C (en) 2007-04-18
US20040053262A1 (en) 2004-03-18
DE60121346T2 (en) 2007-07-19
JP2004525605A (en) 2004-08-26
DK1313762T3 (en) 2006-10-30
CN1446228A (en) 2003-10-01

Similar Documents

Publication Publication Date Title
CY1106187T1 (en) REPRESSION GENE
CY1105895T1 (en) SOLUBLE INTEPLEUKIN-6 RECEPTOR/BINDER CHIMERIC PROTEIN, THEREOF AND USES THEREOF
DK0670899T3 (en) Heat shock proteins and treatment of tumors
ATE332368T1 (en) SELECTION OF PROTEINS USING RNA-PROTEIN FUSIONS
BR0316435A (en) Genetic products differentially expressed in and use of tumors
ATE371727T1 (en) KDR, A HUMAN TYROSINE KINASE RECEPTOR
DE69900746D1 (en) CONTROLLED ADMINISTRATION OF PEPTIDES OR PROTEINS
DE69421624D1 (en) MEDICINE BINDING PROTEIN
DK1121382T3 (en) Interferon-beta fusion proteins and their applications
CY1106323T1 (en) TRANSGENIC INSECT-RESISTANT PLANTS AND METHODS OF IMPROVING DELTA-ENDOTOXIN ACTIVITY AGAINST INSECT TARGETS
EA200000311A1 (en) NEW PROTEIN IMMUNE SYSTEM - KAU
DE60041505D1 (en) INTEGRITY PROTEINS OF BACILLUS THURINGIENSIS
PT839194E (en) VARIANT PROTEIN P53 AND THERAPEUTIC UTILIZATIONS.
CY1105380T1 (en) PREFERRED NEURAL FILAMENT PROTEIN PORTIONS AND METHODS OF USING THEREOF
NO971059D0 (en) Modified human C3 proteins
ATE439441T1 (en) MODIFIED FLUORESCENT PROTEINS
DK1082423T3 (en) Cyclin E2 genes and proteins
BR9710919A (en) Purified protein sr-p70
DK0804577T3 (en) cDNA encoding a BMP type II receptor
DE69831231D1 (en) MODULATORS OF INTRA-CELLULAR INFLAMMATORY, CELL-DATE, AND CELL-LIFE PATHS THAT CONTAIN CARD AND KINASE DOMAINS
YU21292A (en) INSECTICIDALLY EFFECTIVE PEPTIDES
ATE389403T1 (en) INHIBITORS OF PEPTIDE DEFORMYLASE
PT1140994E (en) PROTEINS OF THE EXTERNAL SURFACE, THEIR GENES AND THEIR USE
PT870015E (en) NEW XYLANESES THE GENES THAT ENCODE THEM AND THEIR USES
ATE300294T1 (en) INHIBITORS OF PEPTIDE DEFORMYLASE